Results 81 to 90 of about 5,500,616 (251)

Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.

, 2016
Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.
Caroline Besson (69818), Olivier Hermine (69824), Pascaline Rabiega (2817928), Danielle Canioni (69828), Delphine Bonnet (607285), Juliette Jeannel (3225042), Laurent Alric (336914), Stanislas Pol (254669), Nathanael Lapidus (343063), Frédéric Davi (697381), Patrice Cacoub (38095), Jean-Marie Michot (2817931), Loic Ysebaert (3225039)   +12 more
core   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Lipid droplet profiling during neutrophil differentiation by stimulated Raman scattering microscopy

Biotechnology Progress, EarlyView.
Abstract Lipid droplets (LDs) are dynamic organelles that serve as metabolic hubs and emerging regulators of immune cell fate. Although LDs have been implicated in immune regulation, how LD metabolism is remodeled during neutrophil differentiation and how stage‐specific LD dynamics shape mature neutrophil function remain poorly defined.
Ting‐Jung Sung, Bin Dong, Jingqiao Shen, Yan Tan, Chi Zhang, Xiaoping Bao   +5 more
wiley   +1 more source

Optimizing the Dose and Duration of Therapy for ChronicHepatitis C

Gut and Liver, 2009
Recent studies indicate that antiviral treatment with pegylated interferon alfa and ribavirin for hepatitis C can be individualized based on viral and host characteristics and the pattern of virologic response during the initial months of antiviral ...
doaj   +1 more source

Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study [PDF]

, 2019
Direct-acting antiviral agents (DAAs) are extremely effective in eradicating hepatitis C virus (HCV) in chronically infected patients. However, the protective role of the sustained virologic response (SVR) achieved by second- and third-generation DAAs ...
Sechi L. A., Soardo G., Catena, C., Brizzi, R. F., Catena C., Valenti, L., Colussi G., Brizzi R. F., Colussi, G., Cavarape A., Sechi, L. A., Valenti L., Donnini, D., Donnini D., Soardo, G., Maier, S., Cavarape, A., Maier S.   +17 more
core   +1 more source

Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia

Biotechnology Progress, EarlyView.
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng, Huajian Chen, Man Wang, Toru Yoshitomi, Naoki Kawazoe, Yingnan Yang, Guoping Chen   +6 more
wiley   +1 more source

The virologic response rates (intention-to-treat analysis).

, 2018
The sustained virologic response (SVR) 12 rates of the IFN-free treatment-naïve patients and IFN-free retreatment patients were 97.6% and 80.6% respectively.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C

, 2016
Chih-Wei Tseng,1,2 Ting-Tsung Chang,3,4 Shinn-Jia Tzeng,5 Yu-Hsi Hsieh,1,2 Tsung-Hsing Hung,1,2 Hsiang-Ting Huang,6 Shu-Fen Wu,7 Kuo-Chih Tseng1,2 1Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi ...
Chang TT, Tseng CW, Hsieh YH, Wu SF, Hung TH, Tzeng SJ, Huang HT, Tseng KC   +7 more
core  

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source